figshare
Browse

IP6K1 rewires LKB1 signaling to mediate hyperglycemic endothelial senescence

Download (968.3 kB)
figure
posted on 2025-01-10, 16:15 authored by Changchang Xing, Linhui Shi, Limei Zhu, Tim Aguirre, Ji Qi, Yuanyuan Chen, Yue Liu, Alfred C. Chin, Hong Zhu, Dorothea Fiedler, Alex F. Chen, Chenglai Fu

Diabetes is a major risk factor for cardiovascular disease, but the molecular mechanisms underlying diabetic vasculopathy have been elusive. Here we report that inositol hexakisphosphate kinase 1 (IP6K1) mediates hyperglycemia-induced endothelial senescence by rewiring the liver kinase B1 (LKB1) signaling from activating the adenosine monophosphate-activated protein kinase (AMPK) pathway to the p53 pathway. We found that hyperglycemia upregulated IP6K1, which disrupts the Hsp/Hsc70 and carboxyl terminus of Hsc70-interacting protein (CHIP)-mediated LKB1 degradation, leading to increased expression levels of LKB1. High glucose also strengthens the binding of IP6K1 to AMPK, suppressing the LKB1-mediated AMPK activation. Thus, the elevated LKB1 does not lead to the activation of the AMPK pathway. Instead, it binds more to p53, resulting in p53-dependent endothelial senescence. Endothelial-specific deletion of IP6K1 alleviates, whereas endothelial-specific overexpression of IP6K1 exaggerates the hyperglycemia-induced endothelial senescence. This study reveals a regulatory mechanism of IP6K1 in switching the LKB1/AMPK pathway to LKB1/p53 pathway. IP6K1 represents a potential therapeutic target for treating hyperglycemia-induced endothelial dysfunction.

Funding

This work was supported in part by grants from the Ministry of Science and Technology of China (2021YFA0804803, 2022YFA1104204), the National Key R&D Program of China (2022YFA1104200), and the National Natural Science Foundation of China (82220108021, 82495172, 82421001, 82241027). A.C.C was supported by NIH Medical Scientist Training Program Training Grant T32GM007739 and an American Heart Association Predoctoral Fellowship.

History